NeuroSalt

NeuroSalt Therapeutics is a South Korean biotechnology company dedicated to developing first-in-class therapeutics for neurodegenerative and metabolic diseases. The company leverages breakthrough research on reactive astrocytes, specifically focusing on the pathological overproduction of GABA mediated by the enzyme Monoamine oxidase B (MAO-B). Their lead program, NST-101, is a highly selective and reversible MAO-B inhibitor currently being evaluated for the treatment of Alzheimer's disease and Parkinson's disease. By inhibiting the astrocytic production of GABA, NeuroSalt aims to restore neuronal signaling and alleviate cognitive deficits. Additionally, the company is expanding its pipeline to address obesity, utilizing the same astrocyte-targeting mechanism to regulate metabolism.